Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
H. Lee Moffitt Cancer Center and Research Institute
Medical College of Wisconsin
Novartis
Fred Hutchinson Cancer Center
Children's Oncology Group
Astellas Pharma Inc
St. Jude Children's Research Hospital
Delta-Fly Pharma, Inc.
Astellas Pharma Inc
National Cancer Institute (NCI)
Guangdong Provincial People's Hospital
University of Washington
Sanofi
Children's Oncology Group
Fred Hutchinson Cancer Center
Thomas Jefferson University
Servier
University of Pittsburgh
Medical College of Wisconsin
Wake Forest University Health Sciences
Medical College of Wisconsin
Arog Pharmaceuticals, Inc.
University of Washington
Arog Pharmaceuticals, Inc.
Sumitomo Pharma America, Inc.
Thomas Jefferson University
Fred Hutchinson Cancer Center
University of Washington
Ohio State University Comprehensive Cancer Center
University of Kentucky
Cornerstone Pharmaceuticals
Rush University Medical Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
New York Medical College
The University of Hong Kong
Institute of Hematology & Blood Diseases Hospital, China
Sumitomo Pharma Co., Ltd.
University of Washington
University of Washington
Rush University Medical Center
University of Birmingham
University of Ulm
Polish Adult Leukemia Group
Children's Oncology Group
University of Chicago
Massachusetts General Hospital
University of Chicago
Fred Hutchinson Cancer Center